Budget impact of somatostatin analogs as treatment for metastatic gastroenteropancreatic neuroendocrine tumors in US hospitals

OBJECTIVE: With the introduction of new therapies, hospitals have to plan spending limited resources in a cost-effective manner. To assist in identifying the optimal treatment for patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors, budget impact modeling was us...

Descripción completa

Detalles Bibliográficos
Autores principales: Ortendahl, Jesse D, Pulgar, Sonia J, Mirakhur, Beloo, Cox, David, Bentley, Tanya GK, Phan, Alexandria T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5566387/
https://www.ncbi.nlm.nih.gov/pubmed/28860831
http://dx.doi.org/10.2147/CEOR.S140866

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5566387/
https://www.ncbi.nlm.nih.gov/pubmed/28860831
http://dx.doi.org/10.2147/CEOR.S140866

Ejemplares similares